STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents

Summary

AIDS activists have criticized a research and development agreement between the U.S. government and Gilead Sciences related to patents for an HIV prevention drug as part of a settlement between the parties.